Skip to main content
. 2020 Oct 10;22(10):622–625. doi: 10.1016/j.micinf.2020.10.002

Table 1.

Demographics, baseline characteristics and evolution of 114 COVID-19 patients in Nord Franche-Comte Hospital, France, 2020.

Characteristics Group 1 (Patients with COVID-19 pneumonia) n = 55 Group 2 (Patients without COVID-19 pneumonia) n = 59 p-(value)
Demographics and baseline characteristics of COVID-19 patients
Age (y) (mean, extremes, SD) 68.5 ± 16.7 [32–96] 45.6 ± 16.2 [19–97] <0,001
Sex (Number, %) Male 32 (58.2) 16 (27.1) 0,001
Health care worker (Number, %) 8 (14.5) 34 (57.6) <0,001
Current smoking (Number, %) 8 (14.5) 7 (11.9) 0,672
Comorbidities (Number, %) No 15 (27.3) 41 (69.5) <0,001
Cardio-vascular diseases Hypertension 26 (47.3) 5 (8.5) <0,001
Heart failure 9 (16.4) 1 (1.7) 0,007
Othersa 9 (16.4) 5 (8.5) 0.200
COPDb or asthma 9 (16.4) 5 (8.5) 0,200
Immunosuppressionc 2 (3.6) 2 (3.4) 0,664
Diabetes mellitus 14 (25.5) 2 (3.4) 0,001
Malignancy 7 (12.7) 1 (1.7) 0,024
Charlson comorbidity index (mean, extremes, SD) 3.2 ± 2.8 [0–10] 0.7 ± 1.6 [0–9] <0,001
Clinical outcomes
Hospitalization (Number, %) 52 (94.5) 9 (15.3) <0.001
Duration of hospitalization (days) (mean, SD, extremes) 10.7 ± 9.9 [1–44] 3 ± 2.8 [1–10] 0.026
Oxygen therapy (Number, %) 44 (80) 3 (5.1) <0.001
Days from illness onset to oxygenation (days) (mean, SD, extremes) 6,22 ± 4,26 [1–21] 7.66 ± 5.85 [1–12] 0.582
Patients admitted or transferred to ICU (Number, %) 12 (21.8) 0 <0,001
Days from conventional hospitalization to ICU admission (mean, SD, extremes) 3,90 ± 2,87 [1–11]
IMV (Number, %) 9 (16.4%) 0 0.001
Duration of hospitalization in ICU (mean, extremes, SD) 12,27 ± 10,03 [2–37]
Outcome (Number, %) Discharge 35 (63.6) 58 (98.3) <0.001
Death 20 (36.4) 1 (1.7) <0.001

Bold values signifies p-value < 0.05.

a

Defined by: cardiac arrhythmia, coronary heart disease, stroke, peripheral arterial obstructive disease and thromboembolic disease.

b

COPD: chronic obstructive pulmonary disease.

c

Defined by: transplantation, cirrhosis, long-term steroids therapy, immunomodulators treatments.